化合物 Vabicaserin hydrochloride,Vabicaserin hydrochloride

化合物 Vabicaserin hydrochloride|T13275|TargetMol

價格	￥592	￥1550	￥2270
包裝	1mg	5mg	10mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-12-12

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:化合物 Vabicaserin hydrochloride	英文名稱:Vabicaserin hydrochloride
CAS:887258-94-8	品牌: TargetMol
產(chǎn)地: 美國	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
純度規(guī)格: 98.42%	產(chǎn)品類別: 抑制劑
貨號: T13275

Product Introduction

Bioactivity

名稱	Vabicaserin hydrochloride
描述	Vabicaserin hydrochloride (SCA 136) is a selective agonist of 5-hydroxytryptamine 2C (5-HT2C) receptor (EC50: 8 nM).
體外活性	In Chinese hamster ovary cell membranes, Vabicaserin displaces 125I-(2,5-dimethoxy)phenylisopropylamine binding from human 5-HT2C receptor sites (Ki: 3 nM) and is >50-fold selective over a number of serotonergic, noradrenergic, and dopaminergic receptors. The binding affinity determined for the human 5-HT2B receptor subtype using [3H]5HT is 14 nM. Vabicaserin is a potent and full agonist (EC50, 8 nM; Emax, 100%) in stimulating 5-HT2C receptor-coupled calcium mobilization and exhibits 5-HT2A receptor antagonism and 5-HT2B antagonist or partial agonist activity in transfected cells, depending on the level of receptor expression. Vabicaserin showed a lower affinity at the binding site (22 nM) of 5-HT2C antagonist labeled with [3H]methsulamide. Other binding studies have shown that Vabicaserin has an affinity for 5-HT2B and 5-HT1A receptors with Ki values of 14 and 112 nM, respectively [1].
體內(nèi)活性	The unchanged drug represents less than 19, 20, and 35% of total plasma radioactivity at all the time points examined in mice, rats, and dogs, respectively, after a single oral dose of [14C]Vabicaserin at 50, 5, and 15 mg/kg. The carbamoyl glucuronide (CG) represents approximately 7 to 36% of plasma radioactivity in mice and 2 to 28% of plasma radioactivity in dogs but is not detected in rat plasma after the single [14C]Vabicaserin dose. However, the CG is observed in rat plasma after multiple-dose administration of Vabicaserin at higher doses, and the CG is approximately 20 times less than Vabicaserin based on steady-state AUC0-24 values. The estimated plasma AUC0-24 ratios of CG to the parent drug are 1.5 and 1.7 in mice and dogs after the single [14C]Vabicaserin dose, respectively. The plasma AUC0-24 ratios for the CG to Vabicaserin at steady-state with doses used for safety assessment are less for mice (0.2-0.6) and slightly higher for dogs (1.8-4.0) compared with the single-dose values. The CG is detected in dog urine in similar amounts to the parent drug, although it is not detected in mouse or rat urine after the single [14C]Vabicaserin dose. Radioactivity in a 0- to 24-h bile collection from rats receiving a 5 mg/kg [14C]Vabicaserin dose accounts for 19 and 24% of the administered dose in males and females, respectively. Although the CG is not detected in the urine or feces of rats after a single oral administration, In male rats and 15% in female rats, it represents an average of up to 30% of biliary radioactivity. In monkeys after a single oral 25-mg/kg dose of Vabicaserin, the plasma concentrations of the CG exceeded those of Vabicaserin at all the time points (2-24 h) postdose, although the amount of CG relative to Vabicaserin decreased by 24 h postdose, with ratios of 17.5 at 2 h and 1.7 at 24 h.In monkeys, The CG to Vabicaserin AUC0-24 ratio of 12:1 indicates that the CG is a major metabolite [2].
存儲條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 55 mg/mL (207.71 mM), Sonication is recommended. H2O : 4 mg/mL (15.11 mM), Sonication is recommended.
關(guān)鍵字	Vabicaserin Hydrochloride \| Vabicaserin hydrochloride \| Vabicaserin \| Serotonin Receptor \| SCA-136 \| SCA136 \| Inhibitor \| inhibit \| 5-hydroxytryptamine Receptor \| 5-HT Receptor
相關(guān)產(chǎn)品	Cinchonidine \| Sevoflurane \| Cloperastine hydrochloride \| Alverine citrate \| Amitriptyline hydrochloride \| Olanzapine \| Dapoxetine hydrochloride \| Trazodone hydrochloride \| Mianserin hydrochloride \| Fluoxetine hydrochloride \| Serotonin hydrochloride \| CLOZAPINE N-OXIDE
相關(guān)庫	抗帕金森病化合物庫 \| 經(jīng)典已知活性庫 \| 已知活性化合物庫 \| 神經(jīng)信號分子庫 \| NO PAINS 化合物庫 \| GPCR靶點分子庫 \| 神經(jīng)退行性疾病化合物庫 \| 膜蛋白靶向化合物庫 \| 疼痛相關(guān)化合物庫 \| 藥物功能重定位化合物庫 \| 抗癌臨床化合物庫 \| 抗癌藥物庫

關(guān)鍵字： SCA 136|TargetMol

公司簡介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領(lǐng)域科學(xué)家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個國家和地區(qū)，已發(fā)展成為全球知名的化合物庫和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫，以及多種類型的生化試劑產(chǎn)品，包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學(xué)試劑盒等，此外，我們還建設(shè)有CADD（計算機輔助藥物設(shè)計）研究中心、藥理實驗室、藥化合成平臺三大技術(shù)中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結(jié)果。

成立日期	2013-04-18 （12年）	注冊資本	566.265100萬人民幣
員工人數(shù)	100-500人	年營業(yè)額	￥ 1億以上
主營行業(yè)	天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù)	經(jīng)營模式	貿(mào)易,工廠,試劑,定制,服務(wù)

TargetMol中國（陶術(shù)生物）

VIP 3年

公司成立：12年
注冊資本：566.265100萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營產(chǎn)品：小分子抑制劑、藥物篩選化合物庫、藥物篩選等
公司地址：靜安區(qū)江場三路238號8樓

進入店鋪

詢盤

店內(nèi)推薦

4-壬氧基苯酚|T72049|TargetMol

￥670

普羅地平鹽酸鹽|T13826|TargetMol

￥8310

化合物 Antibacterial agent 27?|T9612|TargetMol

￥358